| All Groups | Placebo | Treatment | P-value |
---|---|---|---|---|
Age (years) | 67 ± 14 | 65 ± 16 | 67 ± 11 | 0.53 |
Gender (n, % Female) | 13/40 (33%) | 6/20 (30%) | 7/20 (35%) | 0.74 |
Race (n, % Caucasian) | 38/40 (95%) | 19/20 (95%) | 19/20(95%) | 1 |
BMI (kg/m2−) | 29 ± 5 | 28 ± 5 | 31 ± 5 | 0.33 |
HR (BPM) | 72 ± 11 | 70 ± 10 | 74 ± 11 | 0.92 |
Systolic BP (mmHg) | 113 ± 16 | 117 ± 19 | 110 ± 14 | 0.38 |
Diastolic BP (mmHg) | 69 ± 10 | 71 ± 10 | 67 ± 10 | 0.42 |
EF (%) | 28 ± 9 | 30 ± 11 | 27 ± 7 | 0.13 |
Ischemic (#, %) | 25/40 (63%) | 14/20 (70%) | 11/20 (55%) | 0.33 |
Nonischemic (#, %) | 15/40 (37%) | 6/20(30%) | 9/20 (45%) | 0.33 |
ACE/ARB (#, %) | 33/40 (83%) | 17/20 (85%) | 16/20 (80%) | 0.68 |
Digoxin (#, %) | 4/40 (10%) | 2/20 (10%) | 2/20 (10%) | 1 |
Beta Blocker (#, %) | 32/40 (80%) | 14/20 (70%) | 18/20 (90%) | 0.11 |
Loop Diuretic (#, %) | 28/40 (70%) | 13/20 (65%) | 15/20 (75%) | 0.49 |
Spironolactone and/or Eplerenone | 31/40 (78%) | 16/20 (80%) | 15/20 (75%) | 0.70 |
Statins (#, %) | 29/40 (73%) | 15/20 (75%) | 14/20 (70%) | 0.72 |